Skip to main content

Select Drug Profiles

Practice Management

Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator

Thanh-Nghia Nguyen, DrPH, MPH, MBA, Jeffrey Trocio, MPH, Stacey Kowal, MS, Cheryl P. Ferrufino, Julie Munakata, MS, Dell South, PharmD

Stakeholder Perspective

Hypothesis Generation: An Essential Component of Informed Healthcare Management

by Michael F. Murphy, MD, PhD

Practice Management

Bundled Payments: Value-Based Care Implications for Providers, Payers, and Patients

Byron C. Scott, MD, MBA, Tricia L. Eminger, MPH

Practice Management

Use of the Prostate Core Mitomic Test in Repeated Biopsy Decision-Making: Real-World Assessment of Clinical Utility in a Multicenter Patient Population

Lorena Legisi, MPH, Elise DeSa, HBSc, M. Nasar Qureshi, MD, PhD

Stakeholder Perspective

Molecular Tests May Aid Clinical Decision-Making and Reduce Healthcare Costs

by Kelly Huang, PhD

Original Research

The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives

Steven R. Feldman, MD, PhD, Bernard Goffe, MD, Gary Rice, MBA, Matthew Mitchell, PharmD, MBA, FAMCP, Mandeep Kaur, MD, MS, Debbie Robertson, MS, RDN, LDN, Debra Sierka, PharmD, Jeffrey A. Bourret, PharmD, Tamara S. Evans, PharmD, MPH, BCPS, Alice Gottlieb, MD, PhD

Stakeholder Perspective

The Challenge of Managing Specialty Drugs for Psoriasis

by Gary M. Owens, MD

Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?

Stanton R. Mehr, Marj P. Zimmerman, BSPharm, MS

Multiple Myeloma, Oncology

The Evolution of Survivorship Care in Multiple Myeloma

John A. Welz, MPH

Conference Correspondent, ASH 2016 - Multiple Myeloma

Findings from the Connect MM Registry: Changes in Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Carfilzomib, Pomalidomide, and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Elotuzumab, Lenalidomide, and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma

Response-Adapted Therapy for Newly Diagnosed Myeloma

Page 100 of 244
Results 991 - 1000 of 2434